Skip to main content

Table 1 Study population baseline demographic and surgical characteristics

From: Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial

CharacteristicsLevosimendan group (n = 94)Placebo group (n = 93)p value
Age (months)a5 (2,11)7 (2,16)0.318
Gender, female, n (%)42 (44.7%)41 (44.1%)1.000
BMI (kg/m2)14.83 ± 2.2114.76 ± 2.130.870
BSA (m2)0.36 ± 0.170.39 ± 0.190.248
RACHS classification, n (%)*  0.146
 RACHS 253 (63.1%)67 (72.0%) 
 RACHS 321 (25.0%)11 (11.8%) 
 RACHS 49 (10.7%)13 (14.0%) 
 RACHS 51 (1.2%)2 (2.2%) 
Down’s syndrome, n (%)3 (3.2%)2 (2.2%)0.660
CPB (min)81 ± 3484 ± 300.479
Cross-clamp (min)46 ± 2351 ± 220.163
  1. Data are means ± standard deviation (SD) for continuous variables and number of subjects (n) and percentage (%) for categorical variables
  2. BSA body surface area, RACHS Risk Adjustment for Congenital Heart Surgery, CPB cardiopulmonary bypass, BMI body mass index
  3. aData are medians [Q1, Q3]
  4. *RACHS classification was used to divide surgical procedures for congenital heart diseases into six categories of increasing predicted operative risk. The greater the score, the higher the risk associated with the procedure